MetaCap

Nuvation Bio (NUVB) vs Rapport Therapeutics (RAPP)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Rapport Therapeutics (RAPP) has outperformed Nuvation Bio (NUVB) over the past year, losing 15.0% versus a loss of 45.6%. Rapport Therapeutics is the larger company by market cap ($1.37 billion vs $1.34 billion), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

NUVB-45.64%RAPP-15.01%
+100%+23%-53%
Nov 21, 20251 yearNov 20, 2026
NUVB+37.18%RAPP+11.35%
+256%+90%-75%
Jun 3, 20245 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

NUVB versus RAPP key metrics
MetricNUVBRAPP
Share price$3.80$23.16
Market cap$1.34B$1.37B
1-day change-0.26%-1.82%
YTD return-57.59%-23.67%
1-year return-45.64%-15.01%
5-year return-53.49%—
EPS (TTM)$-0.39$-3.17
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$62.90M—
Revenue growth (YoY)+698.96%—
Net income (latest FY)$-204.63M$-111.48M
Operating margin-338.72%—
Net margin-325.31%—
52-week high$9.75$52.93
52-week low$3.71$22.06
Distance from 52-week high-61.03%-56.24%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+227.63%+177.25%
Average volume5.24M790.62K
Shares outstanding352.02M59.28M
Employees31084
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • RAPP has outperformed NUVB by 30.6 percentage points over the past year.

About Nuvation Bio

NUVB stock →

Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing product candidates for cancer treatment. The company's lead product candidate is IBTROZI (taletrectinib), a ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer.

Health Care · Biotechnology: Pharmaceutical Preparations · 310 employees

About Rapport Therapeutics

RAPP stock →

Rapport Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company that focuses on the discovery and development of transformational small molecule medicines for patients suffering from central nervous system (CNS) disorders. The company's lead product candidate is receptor associated protein (RAP)-219, an investigational small molecule that is designed to inhibit TARPy8-containing AMPARs with picomolar affinity for the treatment of focal epilepsy and other CNS disorders, including peripheral neuropathic pain and bipolar disorder.

Health Care · Biotechnology: Pharmaceutical Preparations · 84 employees

NUVB vs RAPP FAQ

Which is bigger, Nuvation Bio or Rapport Therapeutics?

Rapport Therapeutics (RAPP) is larger, with a market capitalization of $1.37B compared with $1.34B for Nuvation Bio (NUVB).

Which stock has performed better over the past year, NUVB or RAPP?

RAPP returned -15.01% over the past 12 months, compared with -45.64% for NUVB (price return, excluding dividends). Past performance does not predict future results.

Are Nuvation Bio and Rapport Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons